UB Paderborn / Katalog / Suche / in CDI

1 – 22 von 22

Sortiert nach

TNF-α Antagonist and Vascular Inflammation in Patients with Psoriasis Vulgaris: A Randomized Placebo-Controlled Study

Journal of investigative dermatology, 2017-08, Vol.137 (8), p.1638-1645

2017

Link zum Volltext

Verfügbarkeit prüfen

Efficacy and safety of roflumilast cream for chronic plaque psoriasis with facial/neck and intertriginous area involvement: a post hoc analysis from a randomized controlled trial

British journal of dermatology (1951), 2023-05, Vol.188 (6), p.810-812

2023

Link zum Volltext

Verfügbarkeit prüfen

Real‐world, long‐term treatment patterns of commonly used biologics in Canadian patients with moderate‐to‐severe chronic plaque psoriasis

Journal of dermatology, 2022-01, Vol.49 (1), p.95-105

2022

Link zum Volltext

Verfügbarkeit prüfen

Effect of Ixekizumab Treatment on Work Productivity for Patients With Moderate-to-Severe Plaque Psoriasis: Analysis of Results From 3 Randomized Phase 3 Clinical Trials

JAMA dermatology (Chicago, Ill.), 2016-06, Vol.152 (6), p.661

2016

Link zum Volltext

Verfügbarkeit prüfen

Efficacy and safety of adalimumab in patients with plaque psoriasis who have shown an unsatisfactory response to etanercept

Journal of the American Academy of Dermatology, 2010-08, Vol.63 (2), p.228-234

2010

Link zum Volltext

Verfügbarkeit prüfen

OBSERVE-5: Comparison of Etanercept-Treated Psoriasis Patients From Canada and the United States

Journal of cutaneous medicine and surgery, 2018-05, Vol.22 (3), p.297-303

2018

Link zum Volltext

Verfügbarkeit prüfen

The treatment of moderate to severe psoriasis with a new anti-CD11a monoclonal antibody

Journal of the American Academy of Dermatology, 2001-11, Vol.45 (5), p.665-674

2001

Link zum Volltext

Verfügbarkeit prüfen

A head‐to‐head comparison of ixekizumab vs. guselkumab in patients with moderate‐to‐severe plaque psoriasis: 12‐week efficacy, safety and speed of response from a randomized, double‐blinded trial

British journal of dermatology (1951), 2020-06, Vol.182 (6), p.1348-1358

2020

Link zum Volltext

Verfügbarkeit prüfen

Efficacy and safety of apremilast in patients with moderate to severe plaque psoriasis of the scalp: Results of a phase 3b, multicenter, randomized, placebo-controlled, double-blind study

Journal of the American Academy of Dermatology, 2020-07, Vol.83 (1), p.96-103

2020

Link zum Volltext

Verfügbarkeit prüfen

Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: results from two randomized, placebo-controlled, phase III trials

British journal of dermatology (1951), 2015-10, Vol.173 (4), p.949-961

2015

Link zum Volltext

Verfügbarkeit prüfen

Efficacy and safety of apremilast in patients with moderate-to-severe genital psoriasis: Results from DISCREET, a phase 3 randomized, double-blind, placebo-controlled trial

Journal of the American Academy of Dermatology, 2024-03, Vol.90 (3), p.485-493

2024

Link zum Volltext

Verfügbarkeit prüfen

Drug Survival of IL-12/23, IL-17 and IL-23 Inhibitors for Psoriasis Treatment: A Retrospective Multi-Country, Multicentric Cohort Study

American journal of clinical dermatology, 2021-07, Vol.22 (4), p.567-579

2021

Link zum Volltext

Verfügbarkeit prüfen

Use of capsule endoscopy to identify lesions suggestive of Crohn's disease in patients with moderate to severe psoriasis

Journal of the American Academy of Dermatology, 2017-10, Vol.77 (4), p.755-756

2017

Link zum Volltext

Verfügbarkeit prüfen

Comparative Effectiveness of Biologics Across Subgroups of Patients with Moderate-to-Severe Plaque Psoriasis: Results at Week 12 from the PSoHO Study in a Real-World Setting

Advances in therapy, 2023-03, Vol.40 (3), p.869-886

2023

Link zum Volltext

Verfügbarkeit prüfen

Long-term Efficacy and Safety of Up to 108 Weeks of Ixekizumab in Pediatric Patients With Moderate to Severe Plaque Psoriasis: The IXORA-PEDS Randomized Clinical Trial

JAMA dermatology (Chicago, Ill.), 2022-05, Vol.158 (5), p.533

2022

Link zum Volltext

Verfügbarkeit prüfen

Use of Biologic Therapeutics in Difficult-to-Treat Psoriasis

Journal of cutaneous medicine and surgery, 2009-01, Vol.13 (1), p.6-17

Lynde, Charles

2009

Link zum Volltext

Verfügbarkeit prüfen

Work Productivity and Healthcare Resource Utilization Outcomes for Patients on Etanercept for Moderate-to-Severe Plaque Psoriasis: Results from a 1-Year, Multicentre, Open-Label, Single-Arm Study in a Clinical Setting

Applied health economics and health policy, 2012-09, Vol.10 (5), p.343-353

2012

Link zum Volltext

Verfügbarkeit prüfen

Clobetasol propionate shampoo 0.05% is efficacious and safe for long-term control of moderate scalp psoriasis

The Journal of dermatological treatment, 2010-05, Vol.21 (3), p.185-192

2010

Link zum Volltext

Verfügbarkeit prüfen

The AWARE Study: Methodology and Baseline Characteristics

Journal of cutaneous medicine and surgery, 2009-12, Vol.13 (6_suppl), p.S113-S121

2009

Link zum Volltext

Verfügbarkeit prüfen

Recommendations for incorporating biologicals into management of moderate to severe plaque psoriasis: individualized patient approaches

Journal of cutaneous medicine and surgery, 2006, Vol.9 Suppl 1 (S1), p.18-25

2006

Link zum Volltext

Verfügbarkeit prüfen

The use of alefacept in the treatment of psoriasis

Journal of cutaneous medicine and surgery, 2004-08, Vol.8 Suppl (S1), p.14-18

2004

Link zum Volltext

Verfügbarkeit prüfen

Short-Contact Clobetasol Propionate Shampoo 0.05% Improves Quality of Life in Patients With Scalp Psoriasis

Cutis (New York, N.Y.), 2009-03, Vol.83 (3), p.157-164

2009

Link zum Volltext

Verfügbarkeit prüfen

1 – 22 von 22

Suche als RSS-Feed

Aktive Filter

ThemaLife Sciences & Biomedicine

ThemaPsoriasis - Drug Therapy

ThemaTreatment Outcome

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(21)
Mit Volltextzugriff
(18)

Publikationsform

Artikel
(22)

Sprache

Englisch
(22)
Japanisch
(1)

Erscheinungsjahr

n.n

Thema

Humans
(22)
Science & Technology
(22)
Dermatology
(20)
Female
(15)
Male
(14)
Psoriasis
(12)
Middle Aged
(11)
Severity Of Illness Index
(11)
Adult
(10)
Double-Blind Method
(10)
Etanercept
(7)
Aged
(6)
Biological And Medical Sciences
(5)
Follow-Up Studies
(5)
Medical Sciences
(5)
Biological Products - Therapeutic Use
(4)
Canada
(4)

12 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

TNF-α Antagonist and Vascular Inflammation in Patients with Psoriasis Vulgaris: A Randomized Placebo-Controlled Study

Efficacy and safety of roflumilast cream for chronic plaque psoriasis with facial/neck and intertriginous area involvement: a post hoc analysis from a randomized controlled trial

Real‐world, long‐term treatment patterns of commonly used biologics in Canadian patients with moderate‐to‐severe chronic plaque psoriasis

Effect of Ixekizumab Treatment on Work Productivity for Patients With Moderate-to-Severe Plaque Psoriasis: Analysis of Results From 3 Randomized Phase 3 Clinical Trials

Efficacy and safety of adalimumab in patients with plaque psoriasis who have shown an unsatisfactory response to etanercept

OBSERVE-5: Comparison of Etanercept-Treated Psoriasis Patients From Canada and the United States

The treatment of moderate to severe psoriasis with a new anti-CD11a monoclonal antibody

A head‐to‐head comparison of ixekizumab vs. guselkumab in patients with moderate‐to‐severe plaque psoriasis: 12‐week efficacy, safety and speed of response from a randomized, double‐blinded trial

Efficacy and safety of apremilast in patients with moderate to severe plaque psoriasis of the scalp: Results of a phase 3b, multicenter, randomized, placebo-controlled, double-blind study

Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: results from two randomized, placebo-controlled, phase III trials

Efficacy and safety of apremilast in patients with moderate-to-severe genital psoriasis: Results from DISCREET, a phase 3 randomized, double-blind, placebo-controlled trial

Drug Survival of IL-12/23, IL-17 and IL-23 Inhibitors for Psoriasis Treatment: A Retrospective Multi-Country, Multicentric Cohort Study

Use of capsule endoscopy to identify lesions suggestive of Crohn's disease in patients with moderate to severe psoriasis

Comparative Effectiveness of Biologics Across Subgroups of Patients with Moderate-to-Severe Plaque Psoriasis: Results at Week 12 from the PSoHO Study in a Real-World Setting

Long-term Efficacy and Safety of Up to 108 Weeks of Ixekizumab in Pediatric Patients With Moderate to Severe Plaque Psoriasis: The IXORA-PEDS Randomized Clinical Trial

Use of Biologic Therapeutics in Difficult-to-Treat Psoriasis

Work Productivity and Healthcare Resource Utilization Outcomes for Patients on Etanercept for Moderate-to-Severe Plaque Psoriasis: Results from a 1-Year, Multicentre, Open-Label, Single-Arm Study in a Clinical Setting

Clobetasol propionate shampoo 0.05% is efficacious and safe for long-term control of moderate scalp psoriasis

The AWARE Study: Methodology and Baseline Characteristics

Recommendations for incorporating biologicals into management of moderate to severe plaque psoriasis: individualized patient approaches

The use of alefacept in the treatment of psoriasis

Short-Contact Clobetasol Propionate Shampoo 0.05% Improves Quality of Life in Patients With Scalp Psoriasis

Aktive Filter

Suchergebnisse filtern